{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:09:08Z","timestamp":1774066148107,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is conflicting evidence that MDR1, MRP2 and LRP expression is responsible for chemotherapy resistance. We conducted this study to explore their role in AML therapy outcomes. Bone marrow and peripheral blood samples of 90 AML patients, receiving chemotherapy, were analyzed by real time PCR. Gene expression was calculated by the 2<jats:sup>\u2212\u0394\u0394Ct<\/jats:sup> method. The patients who had a persistent remission were labelled \u2018Good Responder\u2019 (GRes) whereas, those with relapse or drug resistance were labelled \u2018Poor Responders\u2019 (PRes). Higher LRP expression in bone marrow, but not in peripheral blood, was positively associated with persistent remission (p\u2009=\u20090.001), GRes (p\u2009=\u20090.002), 1-year overall as well as disease-free survival (p\u2009=\u20090.02 and p\u2009=\u20090.007, respectively). Marrow and blood MDR1 and MRP2 expression did not differ significantly between the above groups. Logistic regression analysis showed that only a diagnosis of acute promyelocytic leukemia (APL; M3) or high marrow LRP expression significantly predicted a favorable therapeutic outcome. This is the first report showing that high bone marrow LRP expression predicts significant favorable therapeutic outcome. Peripheral blood LRP expression as well as marrow and blood MDR1 and MRP2 expression have no predictive value in AML patients treated with standard dose cytarabine and daunorubicin 3+7 regimen.<\/jats:p>","DOI":"10.1038\/s41598-018-36780-8","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T11:32:59Z","timestamp":1548243179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lung resistance-related protein (LRP) predicts favorable therapeutic outcome in Acute Myeloid Leukemia"],"prefix":"10.1038","volume":"9","author":[{"given":"Bibi","family":"Kulsoom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7667-5838","authenticated-orcid":false,"given":"Tahir Sultan","family":"Shamsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasir Ali","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"36780_CR1","first-page":"434","volume":"57","author":"K Ullah","year":"2007","unstructured":"Ullah, K. et al. Management of acute myeloid leukaemia\u20135 years\u2019 experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi. J Pak Med Assoc 57, 434\u2013439 (2007).","journal-title":"J Pak Med Assoc"},{"key":"36780_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B L\u00f6wenberg","year":"2011","unstructured":"L\u00f6wenberg, B. et al. Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.Cytarabine dose for acute myeloid leukemia. N Engl J Med 364, 1027\u20131036 (2011).","journal-title":"N Engl J Med"},{"key":"36780_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115, 453\u2013474 (2010).","journal-title":"Blood"},{"key":"36780_CR4","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C. et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13, 714\u2013726 (2013).","journal-title":"Nat Rev Cancer"},{"key":"36780_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1365-2141.2004.05319.x","volume":"128","author":"M Schaich","year":"2005","unstructured":"Schaich, M. et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Hematol 128, 324\u2013332 (2005).","journal-title":"Br J Hematol"},{"key":"36780_CR6","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","volume":"89","author":"CP Leith","year":"1997","unstructured":"Leith, C. P. et al. Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups with Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study. Blood 89, 3323\u20133329 (1997).","journal-title":"Blood"},{"key":"36780_CR7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/clinchem\/48.6.811","volume":"48","author":"S Fujimaki","year":"2002","unstructured":"Fujimaki, S. et al. Quantitative Analysis of a MDR1 Transcript for Prediction of Drug Resistance in Acute Leukemia. Clin Chem 48, 811\u2013817 (2002).","journal-title":"Clin Chem"},{"key":"36780_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ygyno.2004.03.035","volume":"94","author":"V Materna","year":"2004","unstructured":"Materna, V. et al. RNA expression of MDR1\/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94, 152\u2013160 (2004).","journal-title":"Gynecol Oncol"},{"key":"36780_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1590\/S1516-31802004000400007","volume":"122","author":"ET Valera","year":"2004","unstructured":"Valera, E. T. et al. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J 122, 166\u2013171 (2004).","journal-title":"Sao Paulo Med J"},{"key":"36780_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3346\/jkms.2006.21.2.253","volume":"21","author":"HJ Huh","year":"2006","unstructured":"Huh, H. J. et al. Prognostic Significance of Multidrug Resistance Gene 1 (MDR1), Multidrug Resistance-related Protein (MRP) and Lung Resistance Protein (LRP) mRNA Expression in Acute Leukemia. J Korean Med Sci 21, 253\u2013258 (2006).","journal-title":"J Korean Med Sci"},{"key":"36780_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1440-1681.2009.05252.x","volume":"37","author":"YH Liu","year":"2010","unstructured":"Liu, Y. H. et al. Multidrug resistance-associated proteins and implications in drug development. Clin Exp Pharmacol Physiol 37, 115\u2013120 (2010).","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"36780_CR12","first-page":"1187","volume":"33","author":"B Noma","year":"2008","unstructured":"Noma, B. et al. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol 33, 1187\u20131194 (2008).","journal-title":"Int J Oncol"},{"key":"36780_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.bjc.6606071","volume":"104","author":"M Yamasaki","year":"2011","unstructured":"Yamasaki, M. et al. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 104, 707\u2013713 (2011).","journal-title":"Br J Cancer"},{"key":"36780_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2183\/pjab.88.416","volume":"88","author":"H Tanaka","year":"2012","unstructured":"Tanaka, H. & Tsukihara, T. Structural studies of large nucleoprotein particles, vaults. Proc Jpn Acad Ser B Phys Biol Sci 88, 416\u2013433 (2012).","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"36780_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0304-3835(96)04542-9","volume":"112","author":"I Sugawara","year":"1997","unstructured":"Sugawara, I. et al. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 112, 23\u201331 (1997).","journal-title":"Cancer Lett"},{"key":"36780_CR16","first-page":"827","volume":"9","author":"H Burger","year":"2003","unstructured":"Burger, H. et al. RNA Expression of Breast Cancer Resistance Protein, Lung Resistance-related Protein, Multidrug Resistance-associated Proteins 1 and 2, and Multidrug Resistance Gene 1 in Breast Cancer: Correlation with Chemotherapeutic Response. Clin Cancer Res 9, 827\u2013836 (2003).","journal-title":"Clin Cancer Res"},{"key":"36780_CR17","first-page":"1097","volume":"24","author":"L Mandoky","year":"2004","unstructured":"Mandoky, L. et al. Expression and prognostic value of the lung resistance-related protein (LRP) in germ cell testicular tumors. Anticancer Res 24, 1097\u20131104 (2004).","journal-title":"Anticancer Res"},{"key":"36780_CR18","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/sj.leu.2402236","volume":"15","author":"DM van der Kolk","year":"2001","unstructured":"van der Kolk, D. M. et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 15, 1544\u20131553 (2001).","journal-title":"Leukemia"},{"key":"36780_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1532\/IJH97.E0624","volume":"86","author":"M Kourti","year":"2007","unstructured":"Kourti, M. et al. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 86, 166\u2013173 (2007).","journal-title":"Int J Hematol"},{"key":"36780_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/1097-0215(20010701)93:1<114::AID-IJC1309>3.0.CO;2-J","volume":"93","author":"IF Faneyte","year":"2001","unstructured":"Faneyte, I. F., Kristel, P. M. & van de Vijver, M. J. Determining MDR1\/P\u2010glycoprotein expression in breast cancer. Int J Cancer 93, 114\u2013122 (2001).","journal-title":"Int J Cancer"},{"key":"36780_CR21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1155\/2013\/728410","volume":"34","author":"M Taheri","year":"2013","unstructured":"Taheri, M. & Mahjoubi, F. MRP1 but not MDR1 is associated with response to neoadjuvant chemotherapy in breast cancer patients. Dis Markers 34, 387\u2013393 (2013).","journal-title":"Dis Markers"},{"key":"36780_CR22","first-page":"4071","volume":"29","author":"M Prenkert","year":"2009","unstructured":"Prenkert, M. et al. Rapid Induction of P-Glycoprotein mRNA and Protein Expression by Cytarabine in HL-60 Cells. Anticancer Res 29, 4071\u20134076 (2009).","journal-title":"Anticancer Res"},{"key":"36780_CR23","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood.V91.12.4480","volume":"91","author":"O Legrand","year":"1998","unstructured":"Legrand, O. et al. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91, 4480\u20134488 (1998).","journal-title":"Blood"},{"key":"36780_CR24","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.1158\/1078-0432.CCR-04-2316","volume":"11","author":"V Dieras","year":"2005","unstructured":"Dieras, V. et al. Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies. Clin Cancer Res 11, 6256\u20136260 (2005).","journal-title":"Clin Cancer Res"},{"key":"36780_CR25","doi-asserted-by":"crossref","first-page":"31466","DOI":"10.18632\/oncotarget.8965","volume":"7","author":"WQ Yuan","year":"2016","unstructured":"Yuan, W. Q. et al. Asclepiasterol, a novel C21 steroidal glycoside derived from Asclepias curassavica, reverses tumor multidrug resistance by down-regulating P-glycoprotein expression. Oncotarget 7, 31466\u201331483 (2016).","journal-title":"Oncotarget"},{"key":"36780_CR26","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1158\/1078-0432.CCR-05-1096","volume":"11","author":"SL Plasschaert","year":"2005","unstructured":"Plasschaert, S. L. et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 11, 8661\u20138668 (2005).","journal-title":"Clin Cancer Res"},{"key":"36780_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2005.08.046","volume":"100","author":"AD Guminski","year":"2006","unstructured":"Guminski, A. D. et al. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol 100, 239\u2013246 (2006).","journal-title":"Gynecol Oncol"},{"key":"36780_CR28","doi-asserted-by":"publisher","first-page":"7030","DOI":"10.1038\/ncomms8030","volume":"6","author":"M Amort","year":"2015","unstructured":"Amort, M. et al. Expression of the vault RNA protects cells from undergoing apoptosis. Nat Commun 6, 7030\u20137040 (2015).","journal-title":"Nat Commun"},{"key":"36780_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00018-008-8364-z","volume":"66","author":"W Berger","year":"2009","unstructured":"Berger, W. et al. Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci 66, 43\u201361 (2009).","journal-title":"Cell Mol Life Sci"},{"key":"36780_CR30","first-page":"7298","volume":"2","author":"MH Mossink","year":"2002","unstructured":"Mossink, M. H. et al. Disruption of the murine major vault protein (MVP\/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res 2, 7298\u20137304 (2002).","journal-title":"Cancer Res"},{"key":"36780_CR31","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1021\/bi047948g","volume":"44","author":"KE Huffman","year":"2005","unstructured":"Huffman, K. E. & Corey, D. R. Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line. Biochemistry 44, 2253\u20132261 (2005).","journal-title":"Biochemistry"},{"key":"36780_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/nass\/nrn110","volume":"52","author":"T Mashima","year":"2008","unstructured":"Mashima, T. et al. Interactions between antitumor drugs and vault RNA. Nucleic Acids Symp Ser (Oxf) 52, 217\u2013218 (2008).","journal-title":"Nucleic Acids Symp Ser (Oxf)"},{"key":"36780_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4077\/CJP.2016.BAF426","volume":"59","author":"YL Chen","year":"2016","unstructured":"Chen, Y. L. et al. Mechanisms underlying lung resistance-related protein (LRP)-mediated doxorubicin resistance of non-small cell lung cancer cells. Chin J Physiol 59, 331\u2013347 (2016).","journal-title":"Chin J Physiol"},{"key":"36780_CR34","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra061808","volume":"355","author":"CT Jordan","year":"2006","unstructured":"Jordan, C. T., Guzman, M. L. & Noble, M. Cancer stem cells. N Engl J Med 355, 1253\u20131261 (2006).","journal-title":"N Engl J Med"},{"key":"36780_CR35","doi-asserted-by":"publisher","first-page":"6663","DOI":"10.7314\/APJCP.2015.16.15.6663","volume":"16","author":"P Bhatia","year":"2015","unstructured":"Bhatia, P. et al. High Expression of Lung Resistance Protein mRNA at Diagnosis Predicts Poor Early Response to Induction Chemotherapy in Childhood Acute Lymphoblastic Leukemia. Asian Pac J Cancer Prev 16, 6663\u20136668 (2015).","journal-title":"Asian Pac J Cancer Prev"},{"key":"36780_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00228-011-1134-0","volume":"68","author":"NA Afsar","year":"2012","unstructured":"Afsar, N. A. et al. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. Eur J Clin Pharmacol 68, 389\u2013395 (2012).","journal-title":"Eur J Clin Pharmacol"},{"key":"36780_CR37","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1177\/147323001103900511","volume":"39","author":"ZJ Chen","year":"2011","unstructured":"Chen, Z. J. et al. Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance. J Int Med Res 39, 1693\u20131700 (2011).","journal-title":"J Int Med Res"},{"key":"36780_CR38","first-page":"1227","volume":"25","author":"SM Hart","year":"1997","unstructured":"Hart, S. M. et al. Expression of the human major vault protein LRP in acute myeloid leukemia. Exp Hematol 25, 1227\u20131232 (1997).","journal-title":"Exp Hematol"},{"key":"36780_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/CMAR.S154608","volume":"10","author":"B Kulsoom","year":"2018","unstructured":"Kulsoom, B. et al. Bax, Bcl-2 and Bax\/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia. Are we ready for Bcl-2 directed therapy? Cancer Manag Res 10, 403\u2013416 (2018).","journal-title":"Cancer Manag Res"},{"key":"36780_CR40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/jjco\/29.7.323","volume":"29","author":"K Suzuki","year":"1999","unstructured":"Suzuki, K. et al. Drug-induced apoptosis andp53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro. Jpn J Clin Oncol 29, 323\u2013331 (1999).","journal-title":"Jpn J Clin Oncol"},{"key":"36780_CR41","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3, 1101\u20131108 (2008).","journal-title":"Nat Protoc"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36780-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36780-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36780-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T04:57:37Z","timestamp":1671253057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36780-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["36780"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-36780-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"25 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"378"}}